专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5803988A Method for manufacturing non-oriented electrical steel sheet showing superior adherence of insulating coated layer 失效
标题翻译：制造无取向电工钢板的方法，其表现出优异的绝缘涂层粘附性
公开(公告)号：US5803988A
公开(公告)日：1998-09-08
申请号：US894394
申请日：1997-08-18
申请人： Byung Keun Bae , Sam Kyu Chang , Jong Soo Woo , Wun Gul Lee
发明人： Byung Keun Bae , Sam Kyu Chang , Jong Soo Woo , Wun Gul Lee
IPC分类号： C21D3/04 , C21D8/12 , C22C38/02 , H01F1/147 , H01F1/18
CPC分类号： C21D8/1288 , C21D8/1272 , C21D8/1277 , H01F1/147 , H01F1/18 , C21D3/04
摘要： The annealing conditions of a cold rolled steel sheet are properly controlled so as to form a dense surface oxide layer, thereby improving the adherence strength of the insulating layer on non-oriented electrical steel sheet. The method includes the following steps. A steel slab is prepared which is composed of in weight %: 0.05% or less of C, 3.5% or less of Si, 1.5% or less of Mn, 0.15% or less of P, 0.015% or less of S, 1.0% or less of Al, one or more elements selected from a group consisting of 0.03-0.30% of Sn, 0.03-0.3% of Sb, 0.03-1.0% of Ni and 0.03-0.50% of Cu, the balance of Fe and unavoidable impurities. The steel slab is reheated, hot rolled, pickled after annealing or without annealing and cold-rolled. A low temperature annealing is carried out on the cold rolled steel sheet at a temperature of 750.degree.-850.degree. C. for 30 seconds to 5 minutes under a humid atmosphere having a dew point of 25.degree.-65.degree. C. A high temperature annealing is carried out on the low-temperature-annealed cold rolled steel sheet at a temperature of 800.degree.-1070.degree. C. for 10 seconds to 3 minutes under a dry atmosphere having a dew point of 0.degree. C. or below. Insulating layers are coated on the surfaces of the high-temperature-annealed steel sheet, and a hardening heat treatment is carried out on the steel sheet.
摘要翻译： PCT No.PCT / KR96 / 00078 Sec。 371日期：1997年8月18日 102（e）1997年8月18日PCT PCT 1996年6月1日PCT公布。公开号WO97 / 22723 日期1996年6月26日冷轧钢板的退火条件被适当地控制，以形成致密的表面氧化物层，从而提高无取向电工钢板上的绝缘层的粘附强度。该方法包括以下步骤。制备钢板，其重量％：C：0.05％以下，Si：3.5％以下，Mn：1.5％以下，P：0.15％以下，S：0.015％以下，1.0％或更少的Al，一种或多种选自Sn，0.03-0.30％的Sn，0.03-0.3％的Sb，0.03-1.0％的Ni和0.03-0.50％的Cu，其余的Fe和不可避免的杂质。再次加热，热轧，退火或不退火冷轧后酸洗。在露点为25〜-65℃的潮湿气氛下，在750〜-850℃的温度下对冷轧钢板进行低温退火30秒〜5分钟。高温退火在露点为0℃以下的干燥气氛下，在800〜-1070℃的温度下在低温退火冷轧钢板上进行10秒钟〜3分钟。在高温退火钢板的表面上涂布绝缘层，对钢板进行硬化热处理。

2. 发明授权

US09731022B2 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant 有权
公开(公告)号：US09731022B2
公开(公告)日：2017-08-15
申请号：US14124436
申请日：2012-05-18
申请人： Yong Il Kim , Kyeong Soo Kim , Jin Cheul Kim , Yo Han Kim , Jae Hyun Park , Jong Soo Woo
发明人： Yong Il Kim , Kyeong Soo Kim , Jin Cheul Kim , Yo Han Kim , Jae Hyun Park , Jong Soo Woo
IPC分类号： A61K31/517 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/36 , A61K47/44 , A61K9/20 , C07D401/12
CPC分类号： A61K47/44 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2031 , A61K9/2077 , A61K31/517 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/36 , C07D401/12
摘要： Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.

3. 发明授权

US09694007B2 Oral complex composition comprising pseudoephedrine and levocetirizine 有权
公开(公告)号：US09694007B2
公开(公告)日：2017-07-04
申请号：US13576338
申请日：2011-01-18
申请人： Jong Soo Woo , Jae Hyun Park , Yong Il Kim , Young Jun Na , Min Jung Kim , Yun Ah Lee
发明人： Jong Soo Woo , Jae Hyun Park , Yong Il Kim , Young Jun Na , Min Jung Kim , Yun Ah Lee
IPC分类号： A61K9/28 , A61K31/495 , A61K9/24 , A61K31/137
CPC分类号： A61K31/495 , A61K9/209 , A61K31/137 , A61K2300/00
摘要： An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.

4. 发明申请

US20140170213A1 CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE 审中-公开
标题翻译：包含MONTELUKAST和LEVOCETIRIZINE的胶囊制剂
公开(公告)号：US20140170213A1
公开(公告)日：2014-06-19
申请号：US14232433
申请日：2012-07-11
申请人： Yong II Kim , Dong Ho Kim , Taek Kwan Kwon , Kyeong Soo Kim , Jae Hyun Park , Jong Soo Woo
发明人： Yong II Kim , Dong Ho Kim , Taek Kwan Kwon , Kyeong Soo Kim , Jae Hyun Park , Jong Soo Woo
IPC分类号： A61K9/48 , A61K31/495 , A61K31/47
CPC分类号： A61K9/4808 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/4816 , A61K31/47 , A61K31/473 , A61K31/495 , A61K31/4965 , C07D215/12 , C07D295/06 , C07D295/08 , A61K2300/00
摘要： Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.
摘要翻译：公开了一种用于预防或治疗过敏性鼻炎和哮喘的胶囊制剂，其包含两个单独的层：（1）包含孟鲁司特或其药学上可接受的盐的蒙特卡斯特层; 和（2）包含左西替利嗪或其药学上可接受的盐的左西替利嗪层; 及其制备方法。根据本发明的胶囊制剂可以完全分离两种活性成分，从而最小化它们之间的反应性并提高产品对抗老化作用的稳定性，从而可以优化治疗效果。

5. 发明申请

US20130243872A1 PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR AND ASPIRIN 审中-公开
标题翻译：包含HMG-COA还原酶抑制剂和阿司匹林的药物复合制剂
公开(公告)号：US20130243872A1
公开(公告)日：2013-09-19
申请号：US13988947
申请日：2011-12-14
申请人： Yong Il Kim , Young Jun Na , Jun Young Choi , Min Jung Kim , Jae Hyun Park , Jong Soo Woo
发明人： Yong Il Kim , Young Jun Na , Jun Young Choi , Min Jung Kim , Jae Hyun Park , Jong Soo Woo
IPC分类号： A61K9/16 , A61K31/40 , G01N33/15 , A61K31/616
CPC分类号： A61K9/16 , A61K9/1611 , A61K9/1676 , A61K9/4808 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/47 , A61K31/505 , A61K31/616 , A61K45/06 , G01N33/15 , A61K2300/00
摘要： Provided is a pharmaceutical composite formulation for preventing or treating cardiovascular diseases, which comprises (1) a first particle comprising an HMG-CoA reductase inhibitor and a basic additive; and (2) a second particle comprising a core containing aspirin and an enteric coating layer coated on said core, wherein the difference in the average diameters of said first and second particles is 100 μm to 800 μm; a method for preparing same; and a method of validating the quality of same. The pharmaceutical composite formulation according to the present invention can improve the stability of an active ingredient and prevent adverse impacts between the active ingredients to thereby enable an accurate quality validation of the pharmaceutical composite formulation.
摘要翻译：提供一种用于预防或治疗心血管疾病的药物复合制剂，其包含（1）包含HMG-CoA还原酶抑制剂和碱性添加剂的第一颗粒; 和（2）包含含有阿司匹林的芯和涂覆在所述芯上的肠溶衣层的第二颗粒，其中所述第一和第二颗粒的平均直径的差异为100μm至800μm; 一种制备方法; 以及验证其质量的方法。根据本发明的药物复合制剂可以改善活性成分的稳定性并防止活性成分之间的不利影响，从而能够对药物复合制剂进行准确的质量验证。

6. 发明申请

US20120301549A1 COMPLEX FORMULATION COMPRISING ASPIRIN COATED WITH BARRIER CONTAINING HYDROPHOBIC ADDITIVE, AND HMG-COA REDUCTASE INHIBITOR 审中-公开
标题翻译：包含含有疏水性添加剂的阻隔剂的阿司匹林的复合配方和HMG-COA还原抑制剂
公开(公告)号：US20120301549A1
公开(公告)日：2012-11-29
申请号：US13576585
申请日：2011-01-26
申请人： Jong Soo Woo , Jae Hyun Park , Yong Il Kim , Young Jun Na , Jun Young Choi , Yun Ah Lee
发明人： Jong Soo Woo , Jae Hyun Park , Yong Il Kim , Young Jun Na , Jun Young Choi , Yun Ah Lee
IPC分类号： A61K9/50 , A61P9/00 , A61K31/60
CPC分类号： A61K31/40 , A61K9/1652 , A61K9/5063 , A61K9/5084 , A61K31/505 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia.
摘要翻译：提供了用于预防或治疗心血管疾病的复合制剂，其包括：a）涂覆有含有疏水性添加剂的屏障的阿司匹林; 和b）HMG-CoA还原酶抑制剂，通过防止由水杨酸引起的HMG-CoA还原酶的稳定性降低而提高储存稳定性，从而用于治疗高血压和高胆固醇血症。

7. 发明申请

US20120301548A1 ORAL COMPLEX COMPOSITION COMPRISING PSEUDOEPHEDRINE AND LEVOCETIRIZINE 有权
标题翻译：包含PSEUDOEPHEDRINE和LEVOCETIRIZINE的口服复合组合物
公开(公告)号：US20120301548A1
公开(公告)日：2012-11-29
申请号：US13576338
申请日：2011-01-18
申请人： Jong Soo Woo , Jae Hyun Park , Yong Il Kim , Young Jun Na , Min Jung Kim , Yun Ah Lee
发明人： Jong Soo Woo , Jae Hyun Park , Yong Il Kim , Young Jun Na , Min Jung Kim , Yun Ah Lee
IPC分类号： A61K9/50 , A61P37/08 , A61P11/00 , A61K31/495
CPC分类号： A61K31/495 , A61K9/209 , A61K31/137 , A61K2300/00
摘要： An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.
摘要翻译：口服复合物组合物，其包含（i）包含可溶胀水凝胶形成剂和伪麻黄碱的核心或其药学上可接受的盐; （ii）包含芯的第一涂层，其包含水溶性物质; 和（iii）在聚乙烯醇，聚维酮，聚乙烯醇 - 聚乙二醇接枝共聚物或它们的混合物上，包含左西替利嗪或其药学上可接受的盐，沉积在第一涂层上的第二涂层具有改善的左西替利嗪释放速率，并且不显示延迟释放行为即使在长期储存期后。因此，本发明的口服复合物组合物可用于治疗多发性或季节性过敏性疾病，包括鼻塞，打喷嚏和鼻漏。

8. 发明授权

US08127516B2 Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same 有权
标题翻译：制备口服快速崩解制剂的方法及其制备和包装方法
公开(公告)号：US08127516B2
公开(公告)日：2012-03-06
申请号：US12654572
申请日：2009-12-23
申请人： Chang Hyun Lee , Jong Soo Woo , Hong Gi Yi , Kyeong Soo Kim , Ho Taek Yim
发明人： Chang Hyun Lee , Jong Soo Woo , Hong Gi Yi , Kyeong Soo Kim , Ho Taek Yim
IPC分类号： B65B63/08
CPC分类号： A61K9/0056 , A61J3/10 , A61K9/2095 , B30B11/02 , B30B11/08 , B65B9/042 , B65B9/045
摘要： A method and packaging machine for preparing rapidly disintegrating formulations for oral administration are disclosed. The present invention is characterized in that a powdery mixture including a pharmaceutically active ingredient and a sugar or a sugar alcohol powder is filled into a packaging material and, thereafter, the mixture, filled in the packaging material, is heated. The present invention can simply and economically prepare an oral formulation which undergoes rapid disintegration in the oral cavity and provides for high-quality administration to patients.
摘要翻译：公开了用于制备用于口服给药的快速崩解制剂的方法和包装机。本发明的特征在于将包含药物活性成分和糖或糖醇粉末的粉末混合物填充到包装材料中，然后将填充在包装材料中的混合物加热。本发明可以简单且经济地制备在口腔中快速崩解并提供给患者高质量给药的口服制剂。

9. 发明申请

US20100048511A1 COMPLEX FORMULATION FOR PREVENTING OR TREATING OSTEOPOROSIS WHICH COMPRISES SOLID DISPERSION OF VITAMIN D OR ITS DERIVATIVE AND BISPHOSPHONATE 审中-公开
标题翻译：用于预防或治疗维生素D或其衍生物和二磷酸盐的固体分散体的复方制剂
公开(公告)号：US20100048511A1
公开(公告)日：2010-02-25
申请号：US12513708
申请日：2007-11-06
申请人： Jong Soo Woo , Hong Gi Yi , Ju Nam Jin
发明人： Jong Soo Woo , Hong Gi Yi , Ju Nam Jin
IPC分类号： A61K31/66 , A61K31/675 , A61K31/663
CPC分类号： A61K31/592 , A61K9/1611 , A61K9/1629 , A61K9/1652 , A61K9/205 , A61K9/2054 , A61K9/2866 , A61K9/5042 , A61K47/6951 , B82Y5/00 , C08B37/0015 , C08L5/16
摘要： Provided is a solid dispersion comprising vitamin D or a derivative thereof and a cyclodextrin; a complex formulation for the prevention or treatment of osteophorosis, which includes the solid dispersion and a bisphosphonate; and a method for preparing said complex formulation. The complex formulation can maintain a constant therapeutic level of vitamin D or a derivative thereof through its improved drug stability, while enhancing the patient compliance by minimizing inconvenience and adverse effects when administered to patients.
摘要翻译：提供了包含维生素D或其衍生物和环糊精的固体分散体; 用于预防或治疗骨质疏松症的复合制剂，其包括固体分散体和双膦酸盐; 以及制备所述复合制剂的方法。复合制剂可以通过其改善的药物稳定性维持维生素D或其衍生物的恒定治疗水平，同时通过最小化给予患者的不便和不利影响来增强患者依从性。

10. 发明申请

US20090175952A1 Cefuroxime axetil granule and process for the preparation thereof 审中-公开
标题翻译：头孢呋辛酯颗粒及其制备方法
公开(公告)号：US20090175952A1
公开(公告)日：2009-07-09
申请号：US10584919
申请日：2005-01-10
申请人： Jong Soo Woo , Hee Chul Chang , Hong Gi Yi
发明人： Jong Soo Woo , Hee Chul Chang , Hong Gi Yi
IPC分类号： A61K31/546 , A61K9/16 , A61P31/00
CPC分类号： A61K9/1623 , A61K9/0095 , A61K9/1635 , A61K9/1652 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K31/545 , A61K31/546
摘要： A cefuroxime axetil granule composition comprising a non-crystalline cefuroxime axetil solid dispersion or a substantially amorphous cefuroxime axetil, sucrose fatty acid ester, methacrylic acid-ethylacrylate copolymer and a disintegrating agent has highly desirable performance characteristics in terms of masking the bitterness of cefuroxime axetil, as well as high bioavailability and stability of cefuroxime axetil, and thus, can be advantageously used for oral administration of cefuroxime axetil.
摘要翻译：包含非结晶头孢呋辛酯固体分散体或基本无定形的头孢呋辛酯，蔗糖脂肪酸酯，甲基丙烯酸 - 乙基丙烯酸酯共聚物和崩解剂的头孢呋辛酯颗粒组合物在掩盖头孢呋辛酯的苦味方面具有非常理想的性能特征，以及头孢呋辛酯的高生物利用度和稳定性，因此可有利地用于头孢呋辛酯的口服给药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式